PTC Therapeutics
PTC Therapeutics is a global biopharmaceutical company that discovers, develops, and commercializes small-molecule drugs and gene therapies for rare genetic disorders including PKU, AADC deficiency, DMD, Friedreich's ataxia, and Huntington's disease, serving patients and healthcare providers across 50+ countries.
- Company typePublic
- Founded1998
- HeadquartersSouth Plainfield, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What PTC Therapeutics does
PTC Therapeutics is a global biopharmaceutical company founded in 1998 and headquartered in Warren, New Jersey (with international headquarters in Dublin, Ireland). The company discovers, develops, and commercializes small-molecule drugs and gene therapies for rare genetic disorders, serving patients with phenylketonuria (PKU), AADC deficiency, Duchenne muscular dystrophy (DMD), Friedreich's ataxia, and Huntington's disease. Its commercial portfolio includes Sephience (oral sepiapterin for PKU, FDA-approved July 2025), Kebilidi (the first FDA-approved AAV gene therapy delivered directly into the brain, for AADC deficiency), Translarna (ataluren for nonsense mutation DMD, approved in Europe), and Emflaza (deflazacort for DMD). Pipeline assets include votoplam (PTC518, partnered with Novartis for Huntington's disease, currently in Phase 3) and vatiquinone (Friedreich's ataxia, pending FDA resubmission following a Complete Response Letter).
PTC operates two proprietary scientific platforms: Splicing (modulating pre-mRNA splicing to control protein production) and Inflammation/Ferroptosis (targeting oxidative stress and inflammation pathways). These platforms have produced multiple first-in-class therapies and generated license revenue (Evrysdi royalties sold to Royalty Pharma in December 2025 for $240 million plus milestones). The company monetizes through direct specialty drug sales across 50+ countries, supplemented by royalty and collaboration revenue. Q1 2026 revenue reached $273 million (with Sephience contributing $124.6 million), and management has guided 2026 total revenue of $1.08–1.18 billion. As of December 2025, PTC reported a cash position of $1.95 billion.
PTC Therapeutics firmographics
Firmographics- Name
- PTC Therapeutics
- Legal name
- PTC Therapeutics, Inc.
- Website
- https://ptcbio.com
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- PTC Therapeutics is a global biopharmaceutical company that discovers, develops, and commercializes small-molecule drugs and gene therapies for rare genetic disorders including PKU, AADC deficiency, DMD, Friedreich's ataxia, and Huntington's disease, serving patients and healthcare providers across 50+ countries.
- Ownership category
- akta.pro rank
PTC Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals — Rare Disease Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where PTC Therapeutics is headquartered
LocationHeadquarters
- HQ city
- South Plainfield
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
PTC Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Product Sales: Commercial sales of approved drugs including Sephience (PKU), Emflaza (DMD), Translarna (nmDMD - Europe only), and Kebilidi (AADC deficiency)
- Royalty Revenue: Royalties from Evrysdi (sold remaining royalties to Royalty Pharma for $240M upfront plus up to $60M milestones in December 2025)
- Collaboration Revenue: Milestone payments and royalties from partnerships including Novartis for Huntington's disease program (received $1B upfront plus up to $1.9B in milestones)
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
PTC Therapeutics product offering
Product offeringCore offering
PTC Therapeutics is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated small-molecule drugs and gene therapies for children and adults with rare genetic disorders of high unmet need. Its commercial portfolio includes Sephience for phenylketonuria, Kebilidi (the first brain-delivered AAV gene therapy) for AADC deficiency, Emflaza for Duchenne muscular dystrophy, and Translarna (Europe only) for nonsense mutation DMD, supported by a pipeline built on proprietary Splicing and Inflammation/Ferroptosis platforms.
Product overview
PTC Therapeutics is a global biopharmaceutical company focused on rare diseases with both commercialized products and a clinical-stage pipeline. The commercial portfolio includes Sephience (oral PKU therapy, FDA-approved July 2025), Kebilidi (AADC deficiency gene therapy, FDA-approved November 2024), Translarna (DMD protein restoration therapy, EU-approved), and Emflaza (DMD corticosteroid). Revenue historically derived from DMD franchise (Translarna, Emflaza) and Evrysdi royalties (sold to Royalty Pharma), now transitioning to Sephience as primary growth driver. The clinical pipeline includes Votoplam for Huntington's disease (Phase 3, partnered with Novartis) and Vatiquinone for Friedreich's ataxia (pending FDA resubmission). PTC operates two scientific platforms: Splicing (modulating pre-mRNA splicing to control protein production) and Inflammation/Ferroptosis (targeting oxidative stress and inflammation pathways).
Differentiator
Problem solved
Functional benefit
Brands
- Sephience: Oral therapy for phenylketonuria (PKU) - approved in US (July 2025), EU, and Japan
- Upstaza/Kebilidi
- Translarna
- Emflaza
- PTC Cares
- Insightful Moments
Products and services
- Sephience (sepiapterin) Oral small-molecule therapy for phenylketonuria (PKU), approved across the U.S., EU, Japan, and Canada for patients of all ages and disease severity levels.
- Kebilidi / Upstaza (eladocagene exuparvovec-tneq) Adeno-associated virus (AAV) gene therapy delivered via intraparenchymal infusion into the putamen for AADC deficiency, the first FDA-approved gene therapy infused directly into the brain.
- Translarna (ataluren) Protein restoration therapy for nonsense mutation Duchenne muscular dystrophy (nmDMD), approved in Europe. PTC withdrew its FDA application after the FDA indicated the data were unlikely to meet effectiveness threshold, and the European authorization non-renewal was adopted.
- Emflaza (deflazacort) Corticosteroid treatment for Duchenne muscular dystrophy, part of PTC's legacy DMD franchise and now facing generic competition.
- Votoplam (PTC518) Investigational daily oral HTT-lowering pill for Huntington's disease, partnered with Novartis. Positive 24-month PIVOT-HD data showed 52% slowing of disease progression at the 10 mg dose, with Phase 3 INVEST-HD underway.
- Vatiquinone Investigational treatment for Friedreich's ataxia. PTC received a Complete Response Letter from the FDA in August 2025, with the FDA indicating an additional study will be required before resubmission.
Quantifiable outcome
- Sephience achieved $124.6M Q1 2026 sales, up 36% sequentially
- +2 more outcomes
Companies that use PTC Therapeutics
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
PTC Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
PTC Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NovartiscoreExclusive global license and collaboration agreement for PTC518 (votoplam) Huntington's disease program. PTC received $1.0 billion upfront and up to $1.9 billion in milestone payments, with Novartis assuming development, manufacturing, and commercial responsibilities after trial completion. PTC retains 40% share of U.S. profits and double-digit tiered royalties on international sales. Novartis initiated global Phase 3 INVEST-HD trial following positive PIVOT-HD data.
Scale indicators14 records
Recent moves6 records
Expansion highlights6 records
PTC Therapeutics competitors and assessment
Company assessmentDirect peers
- Sarepta Therapeutics: Sarepta is the closest DMD competitor, with approved gene therapies (Elevidys) overlapping PTC's DMD franchise (Emflaza/Translarna). Both companies operate in the rare neuromuscular disease space with high-priced, modality-differentiated therapies targeting small populations.
- Ultragenyx Pharmaceutical: Ultragenyx is a rare-disease biotech with direct PKU competition (Crysvita-adjacent metabolic positioning and ongoing work in metabolic rare disease) and a parallel commercial-stage portfolio across multiple rare genetic disorders. Comparable in therapeutic area focus and global launch model.
- Catalyst Pharmaceuticals: Catalyst is a rare-disease commercial biopharma with a similar operating model: small patient populations, high-priced orphan drugs, and global launch infrastructure. Comparable in commercial economics and go-to-market motion.
- Travere Therapeutics: Travere is a smaller rare-disease biopharma with overlap in genetic metabolic and neurological indications. Comparable in commercial-stage rare disease focus and reliance on a small number of high-priced orphan drugs for growth.
- BioMarin Pharmaceutical: BioMarin is the most directly comparable peer — both are commercial-stage rare-disease biopharmas with overlapping PKU franchises (Palynziq/Kuvan vs. Sephience) and parallel strategies in small patient populations with high unmet need. BioMarin also competes in adjacent genetic disease areas like AADC, DMD (indirectly), and enzyme replacement.
Others
- Genentech (Roche): Roche/Genentech is the originator and commercializer of Evrysdi, originally licensed from PTC's splicing platform. Comparable as the partner whose commercialization drove PTC's Evrysdi royalty stream (now sold to Royalty Pharma). Indirectly aligned through shared scientific origin.
- Novartis: Novartis is PTC's strategic partner on votoplam for Huntington's disease ($1B upfront + up to $1.9B in milestones). Comparable as a large biopharma partner assuming late-stage development and commercialization of PTC-discovered assets, providing a benchmark for partner economics and pipeline value.
Broad incumbents
- Vertex Pharmaceuticals: Vertex is a larger commercial-stage rare-disease biopharma with a focused portfolio in cystic fibrosis, sickle cell, and pain, and emerging rare disease pipeline. Comparable in operating model (orphan-drug commercial infrastructure, modality breadth, and rare-disease pricing dynamics) though larger and more diversified.
- Ionis Pharmaceuticals: Ionis is an antisense-based rare-disease biopharma with a similar platform-to-product model and a marketed rare-disease portfolio. Comparable in scientific platform leverage and orphan drug commercial economics.
- Alnylam Pharmaceuticals: Alnylam is a larger rare-disease biopharma built on a single differentiated platform (RNAi) analogous to PTC's Splicing/Inflammation-Ferroptosis platforms. Comparable in modality-driven platform leverage and rare-disease commercial focus, though larger and more diversified.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
PTC Therapeutics social profiles
Digital presencePTC Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
PTC Therapeutics leadership team
Management profileNumber of profiles
Profiles19 records
PTC Therapeutics funding detail
Funding detailFunding overview
Funding rounds16 records
Investors26 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PTC Therapeutics M&A and investment
M&A and investmentM&A3 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PTC Therapeutics
What does PTC Therapeutics do?
PTC Therapeutics is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated small-molecule drugs and gene therapies for children and adults with rare genetic disorders of high unmet need. Its commercial portfolio includes Sephience for phenylketonuria, Kebilidi (the first brain-delivered AAV gene therapy) for AADC deficiency, Emflaza for Duchenne muscular dystrophy, and Translarna (Europe only) for nonsense mutation DMD, supported by a pipeline built on proprietary Splicing and Inflammation/Ferroptosis platforms.
Is PTC Therapeutics a public or private company?
PTC Therapeutics is a public company. It is classified as public and is currently operating.
When was PTC Therapeutics founded?
PTC Therapeutics was founded in 1998. It employs 1,001 to 5,000 people.
Where is PTC Therapeutics based?
PTC Therapeutics is headquartered in South Plainfield, United States, in the North America region.
How does PTC Therapeutics make money?
Three revenue lines are on record. Product Sales are the primary driver. The others are royalty Revenue and collaboration Revenue.
Who are PTC Therapeutics's main competitors?
Direct peers on record are Sarepta Therapeutics, Ultragenyx Pharmaceutical, Catalyst Pharmaceuticals, Travere Therapeutics and BioMarin Pharmaceutical. Others are Genentech (Roche) and Novartis. Broad incumbents are Vertex Pharmaceuticals, Ionis Pharmaceuticals and Alnylam Pharmaceuticals.
Does PTC Therapeutics have an API?
No public API is recorded for PTC Therapeutics.
What industry is PTC Therapeutics in?
PTC Therapeutics's product category is Biopharmaceuticals — Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 325414 and its SIC code is 2834.